United States

Press Releases

Seqirus Receives FDA Approval of AFLURIA QUADRIVALENT® (Influenza Vaccine) for People Five Years of Age and Older in the U.S.
Seqirus announced today that the US Food and Drug Administration (FDA) has approved AFLURIA QUADRIVALENT (Influenza Vaccine) for use in individuals five years of age and older, extending the company’s broad portfolio of influenza vaccine offerings. AFLURIA QUADRIVALENT, which was first approved in the U.S. on August 2016 for individuals 18 and older, helps protect against two influenza A strain viruses and two B strain viruses.3,10 More.

Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas
As hurricane recovery efforts continue in Texas, the U.S. Department of Health and Human Services (DHHS), has requested urgent support to help displaced residents fight the onset of influenza. More.

Seqirus announces major advances in pandemic preparedness
Seqirus, a global leader in the prevention of influenza, announced today that the accelerated development of cell-based manufacturing technology at its state-of-the-art manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats. More.

Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
Seqirus announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2017-2018 influenza season. More.

Seqirus announces next major advancement in cell-based influenza vaccine technology
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today announced the next major advancement in the use of cell-based technology at the state-of-the art manufacturing facility in Holly Springs, North Carolina. More.

Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season
Seqirus announced today that it has begun shipment of its portfolio of influenza vaccines to customers in the US market for the 2016-2017 season. More.

The information presented on this site is intended for US residents only.
© 2018 Seqirus All rights reserved.
Seqirus is a trademark of CSL Limited.

BCSL14-02-0003 06/2014